

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 January 2002 (17.01.2002)

PCT

(10) International Publication Number
WO 02/04406 A2

(51) International Patent Classification⁷: **C07C 237/00**

(21) International Application Number: **PCT/US01/20721**

(22) International Filing Date: **29 June 2001 (29.06.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/216,659 7 July 2000 (07.07.2000) US
60/275,621 13 March 2001 (13.03.2001) US

(71) Applicants: **TRUSTEES OF TUFTS COLLEGE**
[US/US]; Ballou Hall, 4th Floor, Medford, MA 02155
(US). **PARATEK PHARMACEUTICALS, INC.** [US/US];
75 Kneeland Street, Boston, MA 02111 (US).

(72) Inventors: **NELSON, Mark, L.**; 735 Worcester Road,
Wellesley, MA 02481 (US). **FRECHETTE, Roger**; 40
Estate Lane, Reading, MA 01867 (US). **VISKI, Peter**;
887 West Roxbury Parkway, Brookline, MA 02467 (US).
ISMAIL, Mohamed; 5 Hunt Road, Bedford, MA 01730
(US). **BOWSER, Todd**; 88 Haggerty Road, Charlton, MA
01507 (US). **DUMORNAY, Jimmy**; 25 Kendall Street,
Walpole, MA 02081 (US). **RENNIE, Glen**; 11 Clark
Road, South Weymouth, MA 02190 (US). **LIU, Gui**;
73 Edward Street, Medford, MA 02155 (US). **KOZA,**
Darrell; 16 Ledward Avenue, Westerly, RI 02891 (US).
SHEAHAN, Paul; 103 Hayden Rowe Street, Hopkinton,
MA 01748 (US). **STAPLETON, Karen**; 36 Bradmere
Way, Weymouth, MA 02191 (US). **HAWKINS, Paul**; 205

Walden Street, Cambridge, MA 02140 (US). **BHATIA,**
Beena; 1294 Massachusetts Avenue, Arlington, MA
02476 (US). **VERMA, Atul**; 1294 Massachusetts Avenue,
Arlington, MA 02476 (US). **MCINTYRE, Laura**; 188
Franklin Street, Apartment #2, Cambridge, MA 02139
(US). **WARCHOL, Tad**; 411 Great Road, Acton, MA
01720 (US).

(74) Agents: **HANLEY, Elizabeth, A. et al.**; Lahive & Cock-
field, LLP, 28 State Street, Boston, MA 02109 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: **9-SUBSTITUTED MINOCYCLINE COMPOUNDS**

(57) Abstract: The present invention pertains, at least in part, to novel 9- substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

WO 02/04406 A2

9 -SUBSTITUTED MINOCYCLINE COMPOUNDS

Related Applications

This application claims priority to U.S. Provisional Patent Application Serial No. 60/275,621, entitled "9-Substituted Minocycline Compounds," filed on March 13, 2001, and U.S. Provisional Patent Application Serial No. 60/216,580, entitled "9-Substituted Minocycline Compounds," filed on July 7, 2000; both of these applications are hereby incorporated herein by reference. This application is related to U.S. Provisional Application Nos. 60/154,701, filed on September 14, 1999; 60/193,972, filed on March 31, 2000; 60/193,879, filed on March 31, 2000; 60/204,158, filed on May 15, 2000; 60/212,030, filed June 16, 2000; and 60/212,471, filed June 16, 2000, the entire contents of each of which are incorporated herein by reference.

Background of the Invention

The development of the tetracycline antibiotics was the direct result of a systematic screening of soil specimens collected from many parts of the world for evidence of microorganisms capable of producing bacteriocidal and/or bacteriostatic compositions. The first of these novel compounds was introduced in 1948 under the name chlortetracycline. Two years later, oxytetracycline became available. The elucidation of the chemical structure of these compounds confirmed their similarity and furnished the analytical basis for the production of a third member of this group in 1952, tetracycline. A new family of tetracycline compounds, without the ring-attached methyl group present in earlier tetracyclines, was prepared in 1957 and became publicly available in 1967; and minocycline was in use by 1972.

Recently, research efforts have focused on developing new tetracycline antibiotic compositions effective under varying therapeutic conditions and routes of administration. New tetracycline analogues have also been investigated which may prove to be equal to or more effective than the originally introduced tetracycline compounds. Examples include U.S. Patent Nos. 2,980,584; 2,990,331; 3,062,717; 3,165,531; 3,454,697; 3,557,280; 3,674,859; 3,957,980; 4,018,889; 4,024,272; and 4,126,680. These patents are representative of the range of pharmaceutically active tetracycline and tetracycline analogue compositions.


Historically, soon after their initial development and introduction, the tetracyclines were found to be highly effective pharmacologically against rickettsiae; a number of gram-positive and gram-negative bacteria; and the agents responsible for lymphogranuloma venereum, inclusion conjunctivitis, and psittacosis. Hence, tetracyclines became known as "broad spectrum" antibiotics. With the subsequent establishment of their in vitro antimicrobial activity, effectiveness in experimental infections, and pharmacological properties, the tetracyclines as a class rapidly became widely used for therapeutic purposes. However, this widespread use of tetracyclines for both major and minor illnesses and diseases led directly to

the emergence of resistance to these antibiotics even among highly susceptible bacterial species both commensal and pathogenic (*e.g.*, pneumococci and *Salmonella*). The rise of tetracycline-resistant organisms has resulted in a general decline in use of tetracyclines and tetracycline analogue compositions as antibiotics of choice.

5

Summary of the Invention

The invention pertains, at least in part, to minocycline compounds of formula I:



10 wherein:

X is $\text{CHC}(\text{R}^{13}\text{Y}'\text{Y})$, CR^6R^6 , S, NR^6 , or O;

R^2 , R^4 , $\text{R}^{4''}$, $\text{R}^{7'}$ and $\text{R}^{7''}$ are each hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety;

15 R^4 is $\text{NR}^4\text{R}^{4''}$, alkyl, alkenyl, alkynyl, aryl, hydroxyl, halogen, or hydrogen;

$\text{R}^{2'}$, R^3 , R^{10} , R^{11} and R^{12} are each hydrogen or a pro-drug moiety;

R^5 is hydroxyl, hydrogen, thiol, alkanoyl, aroyl, alkaroyl, aryl, heteroaromatic, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, alkyl carbonyloxy, or aryl carbonyloxy;

20 R^6 and R^6 are independently hydrogen, methylene, absent, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;

R^9 is nitro, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylalkyl, amino, arylalkenyl, arylalkynyl, thionitroso, or $-(\text{CH}_2)_{0-3}\text{NR}^{9c}\text{C}(=\text{Z}')\text{ZR}^{9a}$;

25 Z is $\text{CR}^{9d}\text{R}^{9e}$, S, NR^{9b} or O;

Z' is NR^{9f} , O or S;


R^{9a} , R^{9b} , R^{9c} , R^{9d} , R^{9e} and R^{9f} are each independently hydrogen, acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety;

30 R^8 is hydrogen, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;

R^{13} is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;

Y' and Y are each independently hydrogen, halogen, hydroxyl, cyano, sulfhydryl, amino, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl, and pharmaceutically acceptable salts, esters and prodrugs thereof.

- 5 The invention also pertains, at least in part, to 9-substituted minocycline compounds of the formula (II):



(II)

wherein:

R^{4'}, R^{4''}, R^{7'} and R^{7''} are each alkyl; and

- 10 R⁹ is a pyridylethynyl group; an alkenylcarbamate group; a halo group; an alkylacrylate group; a naphthyl group; a haloacetyl group; an alkyl carbamate group; a cyclopentyl or cyclopentenyl group; a benzofuranyl group; a phenylpropiononeamino group; a tosylamino group; a methoxypyridyl group; an alkeneamino group; an N-t-butyl group; a t-butylamide group; a hydroxybutylamino group; a hydroxypropylamino group; a phenyl group; a
15 nitrophenyl group; a nitrophenyl alkynyl group; an aminophenyl group; an alkoxyphenyl group; a halophenyl urea group; a cyanophenyl group; a carboxyphenyl group; an acylphenyl group; an alkylphenyl group; a halophenyl group; an alkoxyphenyl group; a carboxyalkylphenyl group; a phenylalkynyl group; an alkynyl group; an alkylglycineethylester group; a styrene group; a thiophene group; and an alkylaminophospho group; and
20 pharmaceutically acceptable salts, esters and prodrugs thereof.

The invention also pertains to methods of using the minocycline compounds of the invention to treat subjects suffering from states which can be treated using the minocycline compounds of the invention.


- 25 The invention also pertains to pharmaceutical compositions comprising the minocycline compounds of the invention and a pharmaceutically acceptable carrier. The invention also pertains to the use of a minocycline compound of the invention for the manufacture of a medicament, *e.g.*, a medicament for the treatment of a tetracycline responsive state.

Detailed Description of the Invention

- 30 The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other

known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

The invention pertains, at least in part, to minocycline compounds of Formula I:



5 wherein:

X is $\text{CHC}(\text{R}^{13}\text{Y}'\text{Y})$, $\text{CR}^{6'}\text{R}^6$, S, NR^6 , or O;

R^2 , $\text{R}^{4'}$, $\text{R}^{4''}$, $\text{R}^{7'}$ and $\text{R}^{7''}$ are each hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety;

10 R^4 is $\text{NR}^{4'}\text{R}^{4''}$, alkyl, alkenyl, alkynyl, aryl, hydroxyl, halogen, or hydrogen;

$\text{R}^{2'}$, R^3 , R^{10} , R^{11} and R^{12} are each hydrogen or a pro-drug moiety;

R^5 is hydroxyl, hydrogen, thiol, alkanoyl, aroyl, alkaroyl, aryl, heteroaromatic, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, alkyl carbonyloxy, or aryl carbonyloxy;

15 R^6 and $\text{R}^{6'}$ are independently hydrogen, methylene, absent, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;

R^9 is nitro, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylalkyl, amino, arylalkenyl, arylalkynyl, thionitroso, or $-(\text{CH}_2)_{0-3}\text{NR}^{9c}\text{C}(=\text{Z}')\text{ZR}^{9a}$;

20 Z is $\text{CR}^{9d}\text{R}^{9e}$, S, NR^{9b} or O;

Z' is NR^{9f} , O or S;

R^{9a} , R^{9b} , R^{9c} , R^{9d} , R^{9e} and R^{9f} are each independently hydrogen, acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety;

25 R^8 is hydrogen, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;

R^{13} is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;

30 Y' and Y are each independently hydrogen, halogen, hydroxyl, cyano, sulfhydryl, amino, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl, and pharmaceutically acceptable salts, esters and prodrugs thereof.

The term minocycline compounds refers to compounds of formula (I) above. In an embodiment, the term minocycline compounds include compounds wherein X is $\text{CR}^{6'}\text{R}^6$; R^2 ,

$R^{2'}$, R^5 , R^6 , R^8 , R^9 , R^{10} , R^{11} , and R^{12} are each hydrogen; R^4 is $NR^{4'}R^{4''}$; and $R^{4'}$, $R^{4''}$, $R^{7'}$, and $R^{7''}$ are each lower alkyl, *e.g.*, methyl.

Examples of R^9 include substituted and unsubstituted aryl groups. The aryl groups include substituted and unsubstituted heteroaryls (*e.g.*, furanyl, imidazolyl, benzothiophenyl, benzofuranyl, quinolinyl, isoquinolinyl, benzodioxazolyl, benzoxazolyl, benzothiazolyl, 5 benzoimidazolyl, methylenedioxyphenyl, indolyl, thienyl, pyrimidyl, pyrazinyl, purinyl, pyrazolyl, oxazolyl, isooxazolyl, naphthridinyl, thiazolyl, isothiazolyl, or deazapurinyl), substituted or unsubstituted phenyl, and groups with more than one aromatic ring, such as naphthyl.

10 Examples of substituents of R^9 include, but are not limited to, alkyl, alkenyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, alkyloxycarbonyl, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, aralkyl, 15 phosphonato, phosphinato, cyano, amino, acylamino, amido, imino, sulfhydryl, alkylthio, sulfate, arylthio, thiocarboxylate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, cyano, azido, heterocyclyl, alkylaryl, aryl and heteroaryl.

In a further embodiment, the aryl R^9 group is substituted with one or more substituents such as, for example, carboxylate, alkyl, alkenyl, alkynyl, aryl, heterocyclic, cyano, amino, 20 halogen, alkoxy, alkoxycarbonyl, amido, alkylcarbonyl, or nitro.

In another embodiment, R^9 is substituted or unsubstituted alkynyl. The alkynyl R^9 group may be substituted with a substituted or unsubstituted aryl group, such as, for example, phenyl. The possible substituents for the substituted phenyl group include, for example, those listed *supra*, for the aryl R^9 group. Furthermore, the substituted alkynyl R^9 group may be 25 substituted with a heteroaryl (*e.g.*, pyridinyl), alkyl (*e.g.*, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, *etc.*), alkenyl (*e.g.*, ethenyl, propenyl, butenyl, pentenyl, hexenyl, *etc.*), carboxylate, silyl (*e.g.*, trialkylsilyl, *e.g.*, trimethylsilyl), aralkyl, or an alkyloxycarbonyl group.

Each of these groups may also be further substituted, with such substituents as alkyl, 30 alkenyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, alkyloxycarbonyl, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aminoalkyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, aralkyl, phosphonato, phosphinato, cyano, amino, acylamino, amido, imino, 35 sulfhydryl, alkylthio, sulfate, arylthio, thiocarboxylate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, cyano, azido, heterocyclyl, alkylaryl, aryl and heteroaryl.

In a further embodiment, the alkynyl R^9 group is substituted with an aminoalkyl group. The aminoalkyl group may then also be substituted with, for example, an alkyl, alkenyl, alkynyl, acyl, carbonyl, or alkylsulfone group.

In another further embodiment, the alkynyl R^9 group is substituted with a cycloalkenyl group, such as, for example, cyclopentene.

In another embodiment, R^9 is alkyl. The alkyl group may be substituted or unsubstituted. Examples of alkyl groups include, for example, both straight chain, branched and cyclic alkyl groups. For example, alkyl groups include methyl, ethyl, i-propyl, n-propyl, i-butyl, n-butyl, t-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, *etc.* Cyclic alkyl groups include groups with one or more rings, such as, for example; cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, *etc.* In an embodiment, the alkyl R^9 group is 2-cyclopentylethyl.

Examples of substituents of alkyl groups include, for example, halogens (*e.g.*, fluorine, chlorine, bromine, iodine, *etc.*), hydroxyl, alkoxy (*e.g.*, methoxy, ethoxy, propoxy, butoxy, pentoxy, perfluoromethoxy, perchloromethoxy, *etc.*), alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, carboxy, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino, acylamino, amido, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, alkenyl, sulfonato, sulfamoyl, sulfonamido, nitro, alkenyl, cyano, azido, heterocyclyl, alkylaryl, aryl and heteroaryl.

In another embodiment, the minocycline compound of the invention is a compound wherein R^9 is $-NR^{9c}C(=Z')ZR^{9a}$, $-CH_2NR^{9c}C(=Z')ZR^{9a}$, $-(CH_2)_2NR^{9c}C(=Z')ZR^{9a}$, or $-(CH_2)_3NR^{9c}C(=Z')ZR^{9a}$. In certain embodiments, R^9 is $-NR^{9c}C(=Z')ZR^{9a}$ or $-CH_2NR^{9c}C(=Z')ZR^{9a}$. Examples of R^{9c} include hydrogen. Z' may be, for example, S, NH, or O. Examples of Z include NR^{9b} (*e.g.*, when R^{9b} is hydrogen, alkyl, *etc.*), O or S.

Examples of R^{9a} groups include aryl groups such as substituted and unsubstituted phenyl. Examples of possible substituents of aryl R^{9a} groups include, but are not limited to, alkyl (*e.g.*, methyl, ethyl, propyl, butyl, pentyl, hexyl, perfluoromethyl, perchloroethyl, *etc.*), alkenyl, halogen (*e.g.*, fluorine, chlorine, bromine, iodine, *etc.*), hydroxyl, alkoxy (*e.g.*, methoxy, ethoxy, propoxy, perfluoromethoxy, perchloromethoxy, *etc.*), alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino, acylamino, amido, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonato,

sulfamoyl, sulfonamido, nitro, acetyl, alkyl, cyano, azido, heterocyclyl, alkylaryl, aryl and heteroaryl groups.

In certain embodiments, at least one of the substituents of the substituted phenyl is nitro, alkoxy (*e.g.*, methoxy, methylenedioxy, perfluoromethoxy) alkyl (*e.g.*, methyl, ethyl, propyl, butyl, or pentyl), acetyl, halogen (*e.g.*, fluorine, chlorine, bromine, or iodine), or amino (*e.g.*, dialkylamino). In certain embodiments, the alkoxy group is perhalogenated, *e.g.*, perfluoromethoxy.

Examples of aryl R^{9a} groups include, but are not limited to, unsubstituted phenyl, *para*-nitrophenyl, *para*-methoxy phenyl, *para*-perfluoromethoxy phenyl, *para*-acetyl phenyl, 3, 5-methylenedioxyphenyl, 3,5-diperfluoromethyl phenyl, *para*-bromo phenyl, *para*-chloro phenyl, and *para*-fluoro phenyl.

Other examples of aryl R^{9a} groups include substituted and unsubstituted heterocycles (*e.g.*, furanyl, imidazolyl, benzothiophenyl, benzofuranyl, quinolinyl, isoquinolinyl, benzodioxazolyl, benzoxazolyl, benzothiazolyl, benzoimidazolyl, methylenedioxyphenyl, indolyl, thienyl, pyrimidyl, pyrazinyl, purinyl, pyrazolyl, pyrrolidinyl, oxazolyl, isooxazolyl, naphthridinyl, thiazolyl, isothiazolyl, or deazapurinyl) and substituted and unsubstituted biaryl groups, such as naphthyl and fluorene.


R^{9a} also may be substituted or unsubstituted alkyl, *e.g.*, methyl, ethyl, propyl, butyl, pentyl, *etc.* Examples of substituents include but are not limited to halogens (*e.g.*, fluorine, bromine, chlorine, iodine, *etc.*), hydroxyl, alkoxy (*e.g.*, methoxy, ethoxy, propoxy, butoxy, *etc.*), alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxy carbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino, acylamino, amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, alkenyl, heterocyclyl, alkylaryl, aryl and heteroaryl.


R^{9a} also can be substituted or unsubstituted alkenyl. Examples of substituents for alkenyl R^{9a} groups include those listed above for alkyl R^{9a} groups. Examples of alkenyl R^{9a} groups include pent-1-enyl.

In an embodiment, Z' is NH, Z is NH, and R^{9a} is alkyl.

The invention also pertains to compounds wherein R⁹ is aminoalkyl (*e.g.*, aminomethyl). Aminoalkyl R⁹ groups may be further substituted. Examples of substituents include aryl groups, such as, for example substituted or unsubstituted phenyl (*e.g.*, methylenedioxyphenyl or *para*-perfluoromethoxyphenyl), or heteraromatic groups which allows the compound of the invention to perform its intended function.


Examples of minocycline compounds of the invention include those listed in Table 1, as well as the ones listed below:





Pharmaceutically acceptable salts of these compounds are also included. Other compound of the invention are listed in Table 1.

The invention also relates, at least in part, to 9-substituted minocycline compounds of the formula:



(II)

wherein:

$R^{4'}$, $R^{4''}$, $R^{7'}$, and $R^{7''}$ are each alkyl; and

R^9 is a pyridylethynyl group; an alkenylcarbamate group; a halo group; an alkylacrylate group; a naphthyl urea group; a haloacetyl group; an alkyl carbamate group; a cyclopentyl or cyclopentenyl group; a benzofuranyl group; a phenylpropiononeamino group; a tosylamino group; a methoxypyridyl group; an alkeneamino group; an N-t-butyl group; a t-butylamide group; a hydroxybutylamino group; a hydroxypropylamino group; a phenyl group; a nitrophenyl group; a nitrophenyl alkynyl group; an aminophenyl group; a halophenyl urea group; an alkoxyphenyl group; a cyanophenyl group; a carboxyphenyl group; an acylphenyl group; an alkylphenyl group; a halophenyl group; an alkoxyphenyl group; a carboxyalkylphenyl group; a phenylalkynyl group; an alkynyl group; an alkylglycineethylester group; a styrene group; a thiophene group; an alkylaminophospho group; and pharmaceutically acceptable salts thereof.

The term "9-substituted minocycline compound" includes minocycline compounds with a substituent at the 9 position. In another embodiment, the compound is a derivative of minocycline.

5 In an embodiment, R⁹ is an alkenylcarbamate group. Examples of tetracycline compounds with this R⁹ substituent include 9-isopropenyl carbamate minocycline.

In an embodiment, R⁹ is a pyridylethynyl group. Examples of tetracycline compounds with this R⁹ substituent include 9-(2-pyridylethynyl) minocycline.

In an embodiment, R⁹ is a halo group. Examples of tetracycline compounds with this R⁹ substituent include 9-iodo minocycline.

10 In an embodiment, R⁹ is an alkylacrylate group. Examples of tetracycline compounds with this R⁹ substituent include 9-butylacrylate minocycline.

In an embodiment, R⁹ is a naphthyl urea group. Examples of tetracycline compounds with this R⁹ substituent include 9-naphthyl minocycline urea.

15 In an embodiment, R⁹ is a haloacetyl group. Examples of tetracycline compounds with this R⁹ substituent include 9-chloroacetyl minocycline urea.

In an embodiment, R⁹ is an alkyl carbamate group. Examples of tetracycline compounds with this R⁹ substituent include 9-neopentyl minocycline carbamate.

In an embodiment, R⁹ is a cyclopentyl or cyclopentenyl group. Examples of tetracycline compounds with this R⁹ substituent include 9-cyclopentene minocycline.

20 In an embodiment, R⁹ is a benzofuranyl group. Examples of tetracycline compounds with this R⁹ substituent include 9-benzofuranyl minocycline.

In an embodiment, R⁹ is a phenylpropiononeamino group. Examples of tetracycline compounds with this R⁹ substituent include 9-(phenylpropiononeamino) minocycline.

25 In an embodiment, R⁹ is a tosylamino group. Examples of tetracycline compounds with this R⁹ substituent include 9-tosylamino minocycline.

In an embodiment, R⁹ is a methoxypyridyl group. Examples of tetracycline compounds with this R⁹ substituent include 9-(2-methoxy-3-pyridyl) minocycline.

In an embodiment, R⁹ is an alkeneamino group. Examples of tetracycline compounds with this R⁹ substituent include 9-(N-2'-hydroxydecyl-9'-ene-amino) minocycline.

30 In an embodiment, R⁹ is an N-t-butyl group. Examples of tetracycline compounds with this R⁹ substituent include N-t-butyl-minocycline HCl.

In an embodiment, R⁹ is a t-butylamide group. Examples of tetracycline compounds with this R⁹ substituent include 9-BOC-NH minocycline.

35 In an embodiment, R⁹ is a hydroxybutylamino group. Examples of tetracycline compounds with this R⁹ substituent include 9-(N-2'-hydroxybutylamino) minocycline.

In an embodiment, R⁹ is a hydroxypropylamino group. Examples of tetracycline compounds with this R⁹ substituent include 9-(N-3-chloro, 2-hydroxypropylamino) minocycline.

5 In an embodiment, R⁹ is a phenyl group. Examples of tetracycline compounds with this R⁹ substituent include 9-phenyl minocycline HCl and 9-p-tolyl minocycline.

In an embodiment, R⁹ is a nitrophenyl group. Examples of tetracycline compounds with this R⁹ substituent include 9-(3'-nitrophenyl) minocycline.

In an embodiment, R⁹ is a nitrophenyl alkynyl group. Examples of tetracycline compounds with this R⁹ substituent include 9-(4'-nitrophenylethynyl) minocycline.

10 In an embodiment, R⁹ is an aminophenyl group. Examples of tetracycline compounds with this R⁹ substituent include 9-(3-aminophenyl) minocycline.

In an embodiment, R⁹ is a halophenyl urea group. Examples of tetracycline compounds with this R⁹ substituent include 9-(4-chloro,2-trifluoromethylphenyl) minocycline urea.

15 In an embodiment, R⁹ is an alkoxyphenyl group. Examples of tetracycline compounds with this R⁹ substituent include 9-(p-methoxyphenyl) minocycline, 9-(4'-methoxyphenyl) minocycline, and 9-(3,4-methylenedioxyphenyl) minocycline.

In an embodiment, R⁹ is a cyanophenyl group. Examples of tetracycline compounds with this R⁹ substituent include 9-(4'-cyanophenyl) minocycline.

20 In an embodiment, R⁹ is a carboxyalkylphenyl group. Examples of tetracycline compounds with this R⁹ substituent include 9-(4'-carboxyphenyl) minocycline.

In an embodiment, R⁹ is an acylphenyl group. Examples of tetracycline compounds with this R⁹ substituent include 9-(3-formylphenyl) minocycline.

25 In an embodiment, R⁹ is an alkylphenyl group. Examples of tetracycline compounds with this R⁹ substituent include 9-(4'-t-butylphenyl) minocycline.

In an embodiment, R⁹ is a halophenyl group. Examples of tetracycline compounds with this R⁹ substituent include 9-(3-chlorophenyl) minocycline, 9-(2',4'-difluorophenyl) minocycline, 9-(3,4-difluorophenyl) minocycline, 9-(4'-chlorophenyl) minocycline, 9-(3,4-dichlorophenyl) minocycline, and 9-(4'-trifluoromethylphenyl) minocycline.

30 In an embodiment, R⁹ is an alkoxyphenyl group. Examples of tetracycline compounds with this R⁹ substituent include 9-(3-ethoxyphenyl) minocycline.

In an embodiment, R⁹ is a carboxyalkylphenyl group. Examples of tetracycline compounds with this R⁹ substituent include 9-(4-carboxymethylphenyl) minocycline.

35 In an embodiment, R⁹ is a phenylalkynyl group. Examples of tetracycline compounds with this R⁹ substituent include 9-(phenylethynyl) minocycline, 9-(3-hydroxyphenylethynyl) minocycline, 9-(p-tolyethynyl) minocycline, and 9-(p-methoxyphenylethynyl) minocycline.

In an embodiment, R^9 is an alkynyl group. Examples of tetracycline compounds with this R^9 substituent include 9-ethynyl minocycline, 9-(p-fluoroethynyl) minocycline, 9-(trimethylsilylethynyl) minocycline, 9-(propionyl) minocycline, 9-(cyclohexenylethynyl) minocycline, and 9-(1-cyclohexyl-1-hydroxyethynyl) minocycline.

5 In an embodiment, R^9 is an alkylglycineethylester group. Examples of tetracycline compounds with this R^9 substituent include 9-propylglycineethylester minocycline HCl, and 9-methylglycineethylester minocycline.


In an embodiment, R^9 is a styrene group. Examples of tetracycline compounds with this R^9 substituent include 9-(styrene) minocycline, 9-(4'-fluorostyrene) minocycline.

10 In an embodiment, R^9 is a thiophene group. Examples of tetracycline compounds with this R^9 substituent include 9-(2-thiophene) minocycline, and 9-(5'-chloro-2'-thiophene) minocycline.

In an embodiment, R^9 is an alkylaminophospho group. Examples of tetracycline compounds with this R^9 substituent include 9-(p-methoxyphenylaminophospho) minocycline, and 9-(phenylaminophospho) minocycline.

The minocycline compounds of this invention can be synthesized using the methods described in Schemes 1-6.


20 9-substituted minocyclines can be synthesized by the following general method, shown in Scheme 1.



SCHEME 1

25 Generally, 9-substituted minocycline compounds can be synthesized as shown in Scheme 2 by treating minocycline (1A), with sulfuric acid and sodium nitrate. The resulting product is 9-nitro (1B) minocycline. The nitro minocycline compound is then treated with hydrogen gas and a platinum catalyst to yield the 9-amino minocycline compound, 1C. To synthesize 9 derivatives, the 9-amino minocycline compound is treated with $HONO$, to yield the diazonium salt (1D). The salt can subsequently be treated with numerous compounds

possessing an alkene or π bond functional group such as alkenes, aryls, and alkynyls (*e.g.*, R^9Br) yielding the 9-substituted minocycline compound (1E).




SCHEME 2

5


As shown in Scheme 3, minocycline compounds of the invention wherein R^9 is a carbamate or a urea derivative can be synthesized using the following protocol. Minocycline (2A) is treated with $NaNO_2$ under acidic conditions forming 9-nitro minocycline (2B). 9-nitro minocycline (2B) is then treated with H_2 gas and a platinum catalyst to form the 9-amino minocycline derivative (2C). To form the urea derivative (2E), isocyanate (2D) is reacted with the 9-amino minocycline derivative (2C). To form the carbamate (2G), the appropriate acid chloride ester (2F) is reacted with 2C.

10




SCHEME 3

As shown in Scheme 3, minocycline compounds of the invention, wherein R⁹ is a heterocyclic (i.e. thiazole) substituted amino group can be synthesized using the above protocol. 9-amino minocycline (3A) is reacted with Fmoc-isothiocyanate (3B) to produce the protected thiourea (3C). The protected thiourea (3C) is then deprotected yielding the active tetracycline urea or tetracycline thiourea (3D) compound. The tetracycline thiourea (3D) is reacted with an α -haloketone (3E) to produce a thiazole substituted 9-amino minocycline (3F).



SCHEME 4

As shown in Scheme 4, 9- alkenyl minocycline compounds (4A) can be hydrogenated to form alkyl 9- substituted minocycline compounds (4B). Scheme 4 depicts the selective hydrogenation of the 9- position double bond, with hydrogen gas and a palladium/carbon catalyst. Similarly, 9-alkynyl minocyclines also can be hydrogenated to form 9-alkyl minocycline compounds.




SCHEME 5

In Scheme 5, a general synthetic scheme for synthesizing 9-position aryl derivatives of a minocycline compound is shown. In Scheme 5, a Suzuki coupling of an aryl boronic acid with an iodominocycline compound is shown. An iodo minocycline compound (5B) can be synthesized from minocycline by treating minocycline (5A) with at least one equivalent N-iodosuccinimide (NIS) under acidic conditions. The reaction is quenched, and the resulting 9-

iodo minocycline (5B) can then be purified using standard techniques known in the art. To form the aryl derivative, 9-iodo minocycline (5B) is treated with boronic acid (5C) plus aqueous sodium carbonate, and is catalyzed with palladium. The product (5D) can be purified by methods known in the art (such as HPLC). Other 9-aryl minocycline compounds can be synthesized using similar protocols.

The 9-substituted minocycline compounds of the invention can also be synthesized using Stille cross couplings. Stille cross couplings can be performed using an appropriate tin reagent (*e.g.*, R-SnBu₃) and a halogenated tetracycline compound, (*e.g.*, 9-iodominocycline). The tin reagent and the iodominocycline compound can be treated with a palladium catalyst (*e.g.*, Pd(PPh₃)₂Cl₂ or Pd(AsPh₃)₂Cl₂) and, optionally, with an additional copper salt, *e.g.*, CuI. The resulting compound can then be purified using techniques known in the art.



SCHEME 6

The compounds of the invention can also be synthesized using Heck-type cross coupling reactions. As shown in Scheme 6, Heck-type cross-couplings can be performed using a halogenated tetracycline compound (*e.g.*, 9-iodominocycline, 6A), a reactive alkene (6B) or alkyne (6D), and an appropriate palladium or other transition metal catalyst. The resulting 9-substituted alkenyl (6C) or 9-substituted alkynyl (6E) minocycline compound can then be purified using techniques known in the art.

The term "alkyl" includes saturated aliphatic groups, including straight-chain alkyl groups (*e.g.*, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, *etc.*), branched-chain alkyl groups (isopropyl, tert-butyl, isobutyl, *etc.*), cycloalkyl (alicyclic) groups (cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl), alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. The term alkyl further includes alkyl groups, which can further include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone. In certain embodiments, a straight chain or branched chain alkyl has 6 or fewer carbon atoms in its backbone (*e.g.*, C₁-C₆ for straight chain, C₃-C₆ for branched chain), and more preferably 4 or fewer. Likewise, preferred cycloalkyls have

from 3-8 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure. The term C₁-C₆ includes alkyl groups containing 1 to 6 carbon atoms.

Moreover, the term alkyl includes both "unsubstituted alkyls" and "substituted alkyls", the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxy, phosphate, phosphonate, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Cycloalkyls can be further substituted, *e.g.*, with the substituents described above. An "alkylaryl" or an "arylalkyl" moiety is an alkyl substituted with an aryl (*e.g.*, phenylmethyl (benzyl)). The term "alkyl" also includes the side chains of natural and unnatural amino acids.

The term "aryl" includes groups, including 5- and 6-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, phenyl, pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, oxazole, isooxazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like. Furthermore, the term "aryl" includes multicyclic aryl groups, *e.g.*, tricyclic, bicyclic, *e.g.*, naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, methylenedioxyphenyl, quinoline, isoquinoline, naphthridine, indole, benzofuran, purine, benzofuran, deazapurine, or indolizine. Those aryl groups having heteroatoms in the ring structure may also be referred to as "aryl heterocycles", "heterocycles", "heteroaryls" or "heteroaromatics". The aromatic ring can be substituted at one or more ring positions with such substituents as described above, as for example, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonate, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Aryl groups can also be fused or bridged with alicyclic or heterocyclic rings which are not aromatic so as to form a polycycle (*e.g.*, tetralin).

The term "alkenyl" includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double bond.

For example, the term "alkenyl" includes straight-chain alkenyl groups (*e.g.*, ethylenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, *etc.*), branched-chain
5 alkenyl groups, cycloalkenyl (alicyclic) groups (cyclopropenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl), alkyl or alkenyl substituted cycloalkenyl groups, and cycloalkyl or cycloalkenyl substituted alkenyl groups. The term alkenyl further includes alkenyl groups which include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone. In certain embodiments, a straight chain or branched chain alkenyl
10 group has 6 or fewer carbon atoms in its backbone (*e.g.*, C₂-C₆ for straight chain, C₃-C₆ for branched chain). Likewise, cycloalkenyl groups may have from 3-8 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure. The term C₂-C₆ includes alkenyl groups containing 2 to 6 carbon atoms.

Moreover, the term alkenyl includes both "unsubstituted alkenyls" and "substituted
15 alkenyls", the latter of which refers to alkenyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxy, carbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl,
20 alkylthiocarbonyl, alkoxyl, phosphate, phosphonate, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic
25 moiety.

The term "alkynyl" includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but which contain at least one triple bond.

For example, the term "alkynyl" includes straight-chain alkynyl groups (*e.g.*, ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, *etc.*), branched-
30 chain alkynyl groups, and cycloalkyl or cycloalkenyl substituted alkynyl groups. The term alkynyl further includes alkynyl groups which include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone. In certain embodiments, a straight chain or branched chain alkynyl group has 6 or fewer carbon atoms in its backbone (*e.g.*, C₂-C₆ for straight chain, C₃-C₆ for branched chain). The term C₂-C₆ includes alkynyl
35 groups containing 2 to 6 carbon atoms.

Moreover, the term alkynyl includes both "unsubstituted alkynyls" and "substituted alkynyls", the latter of which refers to alkynyl moieties having substituents replacing a

hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxy carbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, 5 alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylaryl amino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. 10

Unless the number of carbons is otherwise specified, "lower alkyl" as used herein means an alkyl group, as defined above, but having from one to five carbon atoms in its backbone structure. "Lower alkenyl" and "lower alkynyl" have chain lengths of, for example, 2-5 carbon atoms.

15 The term "acyl" includes compounds and moieties which contain the acyl radical ($\text{CH}_3\text{CO}-$) or a carbonyl group. The term "substituted acyl" includes acyl groups where one or more of the hydrogen atoms are replaced by for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxy carbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, 20 alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylaryl amino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, 25 trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.

The term "acylamino" includes moieties wherein an acyl moiety is bonded to an amino group. For example, the term includes alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido groups.

30 The term "aroyl" includes compounds and moieties with an aryl or heteroaromatic moiety bound to a carbonyl group. Examples of aroyl groups include phenylcarboxy, naphthyl carboxy, *etc.*

The terms "alkoxyalkyl", "alkylaminoalkyl" and "thioalkoxyalkyl" include alkyl groups, as described above, which further include oxygen, nitrogen or sulfur atoms replacing one or more carbons of the hydrocarbon backbone, *e.g.*, oxygen, nitrogen or sulfur atoms.

35 The term "alkoxy" includes substituted and unsubstituted alkyl, alkenyl, and alkynyl groups covalently linked to an oxygen atom. Examples of alkoxy groups include methoxy, ethoxy, isopropoxy, propoxy, butoxy, and pentoxy groups. Examples of substituted alkoxy

groups include halogenated alkoxy groups. The alkoxy groups can be substituted with groups such as alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxy carbonyloxy, aryloxy carbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxy carbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, 5 alkoxy, phosphate, phosphonate, phosphinate, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic 10 moieties. Examples of halogen substituted alkoxy groups include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, trichloromethoxy, *etc.*

The term "amine" or "amino" includes compounds where a nitrogen atom is covalently bonded to at least one carbon or heteroatom. The term "alkyl amino" includes groups and 15 compounds wherein the nitrogen is bound to at least one additional alkyl group. The term "dialkyl amino" includes groups wherein the nitrogen atom is bound to at least two additional alkyl groups. The term "arylamino" and "diarylamino" include groups wherein the nitrogen is bound to at least one or two aryl groups, respectively. The term "alkylarylamino," "alkylaminoaryl" or "arylaminoalkyl" refers to an amino group which is bound to at least one 20 alkyl group and at least one aryl group. The term "alkaminoalkyl" refers to an alkyl, alkenyl, or alkynyl group bound to a nitrogen atom which is also bound to an alkyl group.

The term "amide" or "aminocarbonyl" includes compounds or moieties which contain a nitrogen atom which is bound to the carbon of a carbonyl or a thiocarbonyl group. The term includes "alkaminocarbonyl" or "alkylaminocarbonyl" groups which include alkyl, alkenyl, 25 aryl or alkynyl groups bound to an amino group bound to a carbonyl group. It includes arylaminocarbonyl groups which include aryl or heteroaryl moieties bound to an amino group which is bound to the carbon of a carbonyl or thiocarbonyl group. The terms "alkylaminocarbonyl," "alkenylaminocarbonyl," "alkynylaminocarbonyl," "arylamino carbonyl," "alkylcarbonylamino," "alkenylcarbonylamino," "alkynylcarbonylamino," and "arylcarbonylamino" are included in term "amide." Amides also 30 include urea groups (aminocarbonylamino) and carbamates (oxycarbonylamino).

The term "carbonyl" or "carboxy" includes compounds and moieties which contain a carbon connected with a double bond to an oxygen atom. Examples of moieties which contain a carbonyl include aldehydes, ketones, carboxylic acids, amides, esters, anhydrides, *etc.*

35 The term "thiocarbonyl" or "thiocarboxy" includes compounds and moieties which contain a carbon connected with a double bond to a sulfur atom.

The term "ether" includes compounds or moieties which contain an oxygen bonded to two different carbon atoms or heteroatoms. For example, the term includes "alkoxyalkyl" which refers to an alkyl, alkenyl, or alkynyl group covalently bonded to an oxygen atom which is covalently bonded to another alkyl group.

5 The term "ester" includes compounds and moieties which contain a carbon or a heteroatom bound to an oxygen atom which is bonded to the carbon of a carbonyl group. The term "ester" includes alkoxycarboxy groups such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentoxycarbonyl, *etc.* The alkyl, alkenyl, or alkynyl groups are as defined above.

10 The term "thioether" includes compounds and moieties which contain a sulfur atom bonded to two different carbon or hetero atoms. Examples of thioethers include, but are not limited to alkthioalkyls, alkthioalkenyls, and alkthioalkynyls. The term "alkthioalkyls" include compounds with an alkyl, alkenyl, or alkynyl group bonded to a sulfur atom which is bonded to an alkyl group. Similarly, the term "alkthioalkenyls" and alkthioalkynyls" refer to compounds
15 or moieties wherein an alkyl, alkenyl, or alkynyl group is bonded to a sulfur atom which is covalently bonded to an alkynyl group.

The term "hydroxy" or "hydroxyl" includes groups with an -OH or -O⁻.

The term "halogen" includes fluorine, bromine, chlorine, iodine, *etc.* The term "perhalogenated" generally refers to a moiety wherein all hydrogens are replaced by halogen
20 atoms.

The terms "polycyclyl" or "polycyclic radical" refer to two or more cyclic rings (*e.g.*, cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls) in which two or more carbons are common to two adjoining rings, *e.g.*, the rings are "fused rings". Rings that are joined through non-adjacent atoms are termed "bridged" rings. Each of the rings of the
25 polycycle can be substituted with such substituents as described above, as for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, alkylaminoacarbonyl, arylalkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkyl carbonyl, alkenylcarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate,
30 phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkyl, alkylaryl, or an aromatic or heteroaromatic
35 moiety.

The term "heteroatom" includes atoms of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, sulfur and phosphorus.

The term "prodrug moiety" includes moieties which can be metabolized *in vivo* to a hydroxyl group and moieties which may advantageously remain esterified *in vivo*. Preferably, the prodrugs moieties are metabolized *in vivo* by esterases or by other mechanisms to hydroxyl groups or other advantageous groups. Examples of prodrugs and their uses are well known in the art (See, *e.g.*, Berge et al. (1977) "Pharmaceutical Salts", *J. Pharm. Sci.* 66:1-19). The prodrugs can be prepared *in situ* during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form or hydroxyl with a suitable esterifying agent. Hydroxyl groups can be converted into esters *via* treatment with a carboxylic acid. Examples of prodrug moieties include substituted and unsubstituted, branch or unbranched lower alkyl ester moieties, (*e.g.*, propionic acid esters), lower alkenyl esters, di-lower alkyl-amino lower-alkyl esters (*e.g.*, dimethylaminoethyl ester), acylamino lower alkyl esters (*e.g.*, acetyloxymethyl ester), acyloxy lower alkyl esters (*e.g.*, pivaloyloxymethyl ester), aryl esters (phenyl ester), aryl-lower alkyl esters (*e.g.*, benzyl ester), substituted (*e.g.*, with methyl, halo, or methoxy substituents) aryl and aryl-lower alkyl esters, amides, lower-alkyl amides, di-lower alkyl amides, and hydroxy amides. Preferred prodrug moieties are propionic acid esters and acyl esters.

It will be noted that the structure of some of the minocycline compounds of this invention includes asymmetric carbon atoms. It is to be understood accordingly that the isomers arising from such asymmetry (*e.g.*, all enantiomers and diastereomers) are included within the scope of this invention, unless indicated otherwise. Such isomers can be obtained in substantially pure form by classical separation techniques and by stereochemically controlled synthesis. Furthermore, the structures and other compounds and moieties discussed in this application also include all tautomers thereof.

The invention also pertains to methods for treating a tetracycline responsive states in subjects, by administering to a subject an effective amount of a minocycline compound of the invention (*e.g.*, a compound of Formula (I) or shown in Table 1), such that the tetracycline responsive state is treated.

The language "tetracycline compound responsive state" includes states which can be treated, prevented, or otherwise ameliorated by the administration of a minocycline compound of the invention. Tetracycline compound responsive states include bacterial infections (including those which are resistant to other tetracycline compounds), cancer, diabetes, and other states for which tetracycline compounds have been found to be active (see, for example, U.S. Patent Nos. 5,789,395; 5,834,450; and 5,532,227). Compounds of the invention can be used to prevent or control important mammalian and veterinary diseases such as diarrhea, urinary tract infections, infections of skin and skin structure, ear, nose and throat infections, wound infection, mastitis and the like. In addition, methods for treating neoplasms using tetracycline compounds of the invention are also included (van der Bozert et al., *Cancer Res.*,

48:6686-6690 (1988)). For certain tetracycline responsive state, a minocycline compound of the invention with little or no antibacterial activity may be desirable.

5 Bacterial infections may be caused by a wide variety of gram positive and gram negative bacteria. The compounds of the invention are useful as antibiotics against organisms which are resistant to other tetracycline compounds. The antibiotic activity of the tetracycline compounds of the invention may be determined using the method discussed in Example 2, or by using the in vitro standard broth dilution method described in Waitz, J.A., *National Commission for Clinical Laboratory Standards, Document M7-A2*, vol. 10, no. 8, pp. 13-20, 2nd edition, Villanova, PA (1990).

10 The minocycline compounds may also be used to treat infections traditionally treated with tetracycline compounds such as, for example, rickettsiae; a number of gram-positive and gram-negative bacteria; and the agents responsible for lymphogranuloma venereum, inclusion conjunctivitis, psittacosis. The tetracycline compounds may be used to treat infections of, e.g., *K. pneumoniae*, *Salmonella*, *E. hirae*, *A. baumannii*, *B. catarrhalis*, *H. influenzae*, *P.*
15 *aeruginosa*, *E. faecium*, *E. coli*, *S. aureus* or *E. faecalis*. In one embodiment, the minocycline compound is used to treat a bacterial infection that is resistant to other tetracycline antibiotic compounds. The minocycline compound of the invention may be administered with a pharmaceutically acceptable carrier.

The language "effective amount" of the compound is that amount necessary or
20 sufficient to treat or prevent a tetracycline compound responsive state. The effective amount can vary depending on such factors as the size and weight of the subject, the type of illness, or the particular minocycline compound. For example, the choice of the minocycline compound can affect what constitutes an "effective amount". One of ordinary skill in the art would be able to study the aforementioned factors and make the determination regarding the effective
25 amount of the minocycline compound without undue experimentation.

The invention also pertains to methods of treatment against microorganism infections and associated diseases. The methods include administration of an effective amount of one or more minocycline compounds to a subject. The subject can be either a plant or, advantageously, an animal, e.g., a mammal, e.g., a human.

30 In the therapeutic methods of the invention, one or more minocycline compounds of the invention may be administered alone to a subject, or more typically a compound of the invention will be administered as part of a pharmaceutical composition in mixture with conventional excipient, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral, oral or other desired administration and which do not
35 deleteriously react with the active compounds and are not deleterious to the recipient thereof.

The invention also pertains to pharmaceutical compositions comprising a therapeutically effective amount of a minocycline compound and, optionally, a pharmaceutically acceptable carrier.

5 The language "pharmaceutically acceptable carrier" includes substances capable of being coadministered with the minocycline compound(s), and which allow both to perform their intended function, *e.g.*, treat or prevent a tetracycline responsive state. Suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions, alcohol, vegetable oils, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, 10 petroethral fatty acid esters, hydroxymethyl-cellulose, polyvinylpyrrolidone, *etc.* The pharmaceutical preparations can be sterilized and if desired mixed with auxiliary agents, *e.g.*, lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously react with the active compounds of the invention.

15 The minocycline compounds of the invention that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of the minocycline compounds of the invention that are basic in nature are those that form non-toxic acid addition salts, *i.e.*, salts containing pharmaceutically acceptable anions, such as the hydrochloride, hydrobromide, 20 hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, *p*-toluenesulfonate and palmoate [*i.e.*, 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)] salts. Although such salts must be 25 pharmaceutically acceptable for administration to a subject, *e.g.*, a mammal, it is often desirable in practice to initially isolate a minocycline compound of the invention from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt. The acid addition salts 30 of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained. The preparation of other minocycline compounds of the invention not specifically described in the foregoing 35 experimental section can be accomplished using combinations of the reactions described above that will be apparent to those skilled in the art.

The preparation of other minocycline compounds of the invention not specifically described in the foregoing experimental section can be accomplished using combinations of the reactions described above that will be apparent to those skilled in the art.

5 The minocycline compounds of the invention that are acidic in nature are capable of forming a wide variety of base salts. The chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those minocycline compounds of the invention that are acidic in nature are those that form non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to those derived from such pharmaceutically acceptable cations such as alkali metal cations (*e.g.*, potassium and sodium)
10 and alkaline earth metal cations (*e.g.*, calcium and magnesium), ammonium or water-soluble amine addition salts such as N-methylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines. The pharmaceutically acceptable base addition salts of minocycline compounds of the invention that are acidic in nature may be formed with pharmaceutically acceptable cations by
15 conventional methods. Thus, these salts may be readily prepared by treating the minocycline compound of the invention with an aqueous solution of the desired pharmaceutically acceptable cation and evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, a lower alkyl alcohol solution of the minocycline compound of the invention may be mixed with an alkoxide of the desired metal and the solution subsequently evaporated
20 to dryness.

The preparation of other minocycline compounds of the invention not specifically described in the foregoing experimental section can be accomplished using combinations of the reactions described above that will be apparent to those skilled in the art.

25 The minocycline compounds of the invention and pharmaceutically acceptable salts thereof can be administered via either the oral, parenteral or topical routes. In general, these compounds are most desirably administered in effective dosages, depending upon the weight and condition of the subject being treated and the particular route of administration chosen. Variations may occur depending upon the species of the subject being treated and its individual response to said medicament, as well as on the type of pharmaceutical formulation chosen and
30 the time period and interval at which such administration is carried out.

The pharmaceutical compositions of the invention may be administered alone or in combination with other known compositions for treating tetracycline responsive states in a subject, *e.g.*, a mammal. Preferred mammals include pets (*e.g.*, cats, dogs, ferrets, *etc.*), farm animals (cows, sheep, pigs, horses, goats, *etc.*), lab animals (rats, mice, monkeys, *etc.*), and
35 primates (chimpanzees, humans, gorillas). The language "in combination with" a known composition is intended to include simultaneous administration of the composition of the invention and the known composition, administration of the composition of the invention first,

followed by the known composition and administration of the known composition first, followed by the composition of the invention. Any of the therapeutically composition known in the art for treating tetracycline responsive states can be used in the methods of the invention.

The minocycline compounds of the invention may be administered alone or in
5 combination with pharmaceutically acceptable carriers or diluents by any of the routes previously mentioned, and the administration may be carried out in single or multiple doses. For example, the novel therapeutic agents of this invention can be administered advantageously in a wide variety of different dosage forms, i.e., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches,
10 hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, *etc.* Moreover, oral pharmaceutical compositions can be suitably sweetened and/or flavored. In general, the therapeutically-effective compounds of this invention are present in such dosage
15 forms at concentration levels ranging from about 5.0% to about 70% by weight.

For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders
20 like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tableting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired
25 for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.

For parenteral administration (including intraperitoneal, subcutaneous, intravenous,
30 intradermal or intramuscular injection), solutions of a therapeutic compound of the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably buffered (preferably pH greater than 8) if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable for intravenous injection purposes. The oily solutions are suitable for intraarticular, intramuscular and
35 subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art. For parenteral application, examples of suitable preparations include solutions,

preferably oily or aqueous solutions as well as suspensions, emulsions, or implants, including suppositories. Therapeutic compounds may be formulated in sterile form in multiple or single dose formats such as being dispersed in a fluid carrier such as sterile physiological saline or 5% saline dextrose solutions commonly used with injectables.

5 Additionally, it is also possible to administer the compounds of the present invention topically when treating inflammatory conditions of the skin. Examples of methods of topical administration include transdermal, buccal or sublingual application. For topical applications, therapeutic compounds can be suitably admixed in a pharmacologically inert topical carrier such as a gel, an ointment, a lotion or a cream. Such topical carriers include water, glycerol,
10 alcohol, propylene glycol, fatty alcohols, triglycerides, fatty acid esters, or mineral oils. Other possible topical carriers are liquid petrolatum, isopropylpalmitate, polyethylene glycol, ethanol 95%, polyoxyethylene monolaurate 5% in water, sodium lauryl sulfate 5% in water, and the like. In addition, materials such as anti-oxidants, humectants, viscosity stabilizers and the like also may be added if desired.

15 For enteral application, particularly suitable are tablets, dragees or capsules having talc and/or carbohydrate carrier binder or the like, the carrier preferably being lactose and/or corn starch and/or potato starch. A syrup, elixir or the like can be used wherein a sweetened vehicle is employed. Sustained release compositions can be formulated including those wherein the active component is protected with differentially degradable coatings, *e.g.*, by
20 microencapsulation, multiple coatings, *etc.*

 In addition to treatment of human subjects, the therapeutic methods of the invention also will have significant veterinary applications, *e.g.* for treatment of livestock such as cattle, sheep, goats, cows, swine and the like; poultry such as chickens, ducks, geese, turkeys and the like; horses; and pets such as dogs and cats. Also, the compounds of the invention may be used
25 to treat non-animal subjects, such as plants.

 It will be appreciated that the actual preferred amounts of active compounds used in a given therapy will vary according to the specific compound being utilized, the particular compositions formulated, the mode of application, the particular site of administration, *etc.* Optimal administration rates for a given protocol of administration can be readily ascertained
30 by those skilled in the art using conventional dosage determination tests conducted with regard to the foregoing guidelines.

 In general, compounds of the invention for treatment can be administered to a subject in dosages used in prior minocycline therapies. See, for example, the *Physicians' Desk Reference*. For example, a suitable effective dose of one or more compounds of the invention will be in the
35 range of from 0.01 to 100 milligrams per kilogram of body weight of recipient per day, preferably in the range of from 0.1 to 50 milligrams per kilogram body weight of recipient per day, more preferably in the range of 1 to 20 milligrams per kilogram body weight of recipient

per day. The desired dose is suitably administered once daily, or several sub-doses, *e.g.* 2 to 5 sub-doses, are administered at appropriate intervals through the day, or other appropriate schedule.

It will also be understood that normal, conventionally known precautions will be taken regarding the administration of minocyclines generally to ensure their efficacy under normal use circumstances. Especially when employed for therapeutic treatment of humans and animals *in vivo*, the practitioner should take all sensible precautions to avoid conventionally known contradictions and toxic effects. Thus, the conventionally recognized adverse reactions of gastrointestinal distress and inflammations, the renal toxicity, hypersensitivity reactions, changes in blood, and impairment of absorption through aluminum, calcium, and magnesium ions should be duly considered in the conventional manner.

In one embodiment, the minocycline compounds of the invention do not include those described in U.S. Patent Application Serial No. 09/823,884, incorporated herein by reference.

Furthermore, the invention also pertains to the use of a minocycline compound of formula I or II, for the preparation of a medicament. The medicament may include a pharmaceutically acceptable carrier and the minocycline compound is an effective amount, *e.g.*, an effective amount to treat a tetracycline responsive state.

EXEMPLIFICATION OF THE INVENTION

Compounds of the invention may be made as described below, with modifications to the procedure below within the skill of those of ordinary skill in the art.

Example 1: Preparation of Minocycline Compounds of the Invention

Preparation of 9-Iodominocycline

To 200ml of 97% methanesulfonic acid was slowly added, at ambient temperature, portionwise [30g;56.56mM] of minocycline-*bis*-hydrochloride salt. The dark yellow brown solution was then stirred at ambient temperature while [38g;169.7mM] of N-iodosuccinimide was added, in six equal portions, over 3.0 hours time. The reaction was monitored via analytical LC, noting the disappearance of the starting material.

The reaction was slowly quenched into 2L of ice cold water containing [17.88g;1134.1mM] of sodium thiosulfate with rapid stirring. This quench was stirred for approximately 30 minutes at ambient temperature. The aqueous layer was then extracted with 6x200ml of ethyl acetate before the aqueous was poured onto [259.8g;3.08M] of sodium hydrogen carbonate containing 300ml of n-butanol. The phases were split and the aqueous extracted with 4x250ml of n-butanol. The organic fractions were combined and washed with 3x250ml of water and once with 250ml of saturated brine. The resulting organic phase was

reduced to dryness under reduced pressure. The residue was suspended in methanol (~600ml) and anhydrous HCl gas was bubbled into this mixture until solution occurred. This solution was reduced to dryness under reduced pressure. The filtrates were reduced to dryness under reduced pressure. The resulting material was triturated with 300ml of methyl t-butyl ether and isolated via filtration. This material was redissolved in 300ml of methanol and treated with 0.5g of wood carbon, filtered and filtrates reduced to dryness under reduced pressure. The material was again powdered under methyl t-butyl ether, isolated via suction filtration and washed with more ether, and finally hexanes. The material was vacuum dried to give 22.6g of a light yellow brown powder.


General Procedure For Preparation of 9-Alkynyl Minocycline Compounds

1 mmol 9-iodo minocycline, 50mg tetrakis triphenylphosphinato palladate, 12 mg palladium acetate, 32mg copper (I) iodide are dissolved/suspended in 10ml acetonitrile. 2 to 5ml triethylamine and 3 to 5 mmol alkynyl derivative is added. The reaction mixture is vigorously stirred between ambient temperature to 70°C. The reaction time is 2-24 hours. When the reaction is completed the dark suspension is filtered through a celite bed and concentrated. The crude product is purified by prep HPLC. The combined fractions are concentrated and taken up in ~1ml methanol.. ~3ml HCl saturated methanol is added, and the product is precipitated with ether.

General Procedure For Preparation of 9-Aryl Minocycline Compounds

0.15mmol of 9-iodominocycline, PdOAc (3.2mg), 229µl 2M Na₂CO₃ and 2 equivalents of phenyl boronic acid were dissolved/suspended in 10ml methanol. The reaction flask was purged with argon and the reaction run for a minimum of four hours or until HPLC monitoring shows consumption of starting material and/or the appearance of products. The suspension was filtered through celite, and subject to purification by prep HPLC on a divinylbenzene column.


Compound OU (9-(4-Trifluoromethoxyphenylureido)-Methyl Minocycline)



9C
SCHEME 7

To 3 mL of dimethylformamide was added 150 mg (0.25 mmol) of 9-methyl aminomincycline trihydrochloride and 67 mL (0.50 mmol) of triethylamine at 25 °C. With stirring, 75 mL (0.50 mmol) of 4-trifluoromethoxyphenylisocyanate was added and the resulting reaction mixture was stirred at 25 °C for two hours. The reaction was monitored by analytical HPLC (4.6 x 50mm reversed phase Luna C18 column, 5 minute linear gradient 1-100% B buffer, A buffer was water with 0.1% trifluoroacetic acid, B buffer was acetonitrile with 0.1% trifluoroacetic acid). Upon completion, the reaction was quenched with 1 mL of water and the pH adjusted to approximately 2.0 with concentrated HCl. The solution was filtered and the compound purified by preparative HPLC. The yield of compound OU was 64 mg (37% yield). The purity of Compound OU was 95% determined by LCMS (M+1 = 690).

Compound LA (9-(4'Carboxy phenyl) Minocycline)



SCHEME 8

15

In a clean, dry reaction vessel, was placed 9-iodominocycline [500mg; 0.762mmoles] bis HCl salt, palladium (II) acetate [17.2mg; 0.076mmoles] along with 10ml of reagent grade methanol. The solution was immediately purged, with stirring, with a stream of argon gas for approximately 5 minutes. The reaction vessel was brought to reflux and to it was sequentially added via syringe 2M potassium carbonate solution [1.91ml; 3.81mmoles], followed by a solution of p-carboxyphenyl boronic acid [238.3mg; 1.53mmoles] in 5ml of reagent DMF. Both of these solutions were previously degassed with argon gas for approximately 5 minutes. The reaction was heated for 45 minutes, the progress was monitored via reverse phase HPLC. The reaction was suctioned filtered through a pad of diatomaceous earth and washed the pad with DMF. The filtrates were reduced to an oil under vacuum and residue treated with t-butylmethyl ether. Crude material was purified via reverse phase HPLC on DVB utilizing a gradient of water and methanol/acetonitrile containing 1.0% trifluoroacetic acid. Product confirmed by mass spectrum: found M+1 578.58; the structure corroborated with ¹H NMR.

30

Example 2: *In vitro* Minimum Inhibitory Concentration (MIC) Assay

The following assay is used to determine the efficacy of minocycline compounds against common bacteria. 2 mg of each compound is dissolved in 100 µl of DMSO. The solution is then added to cation-adjusted Mueller Hinton broth (CAMHB), which results in a final compound concentration of 200 µg per ml. The minocycline compound solutions are

35

diluted to 50 μ L volumes, with a test compound concentration of .098 μ g/ml. Optical density (OD) determinations are made from fresh log-phase broth cultures of the test strains. Dilutions are made to achieve a final cell density of 1×10^6 CFU/ml. At OD=1, cell densities for different genera should be approximately:

5	<i>E. coli</i>	1×10^9 CFU/ml
	<i>S. aureus</i>	5×10^8 CFU/ml
	<i>Enterococcus sp.</i>	2.5×10^9 CFU/ml

50 μ l of the cell suspensions are added to each well of microtiter plates. The final cell density should be approximately 5×10^5 CFU/ml. These plates are incubated at 35°C in an ambient air incubator for approximately 18 hr. The plates are read with a microplate reader and are visually inspected when necessary. The MIC is defined as the lowest concentration of the minocycline compound that inhibits growth. Compounds of the invention indicate good inhibition of growth.











In Table 1, compounds which were good inhibitors of growth of a particular bacteria are indicated with *, compounds which were very good inhibitors of a particular bacteria are indicated with **, and compounds which were particularly good inhibitors of a particular bacteria are indicated with ***.

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of the present invention and are covered by the following claims. The contents of all references, patents, and patent applications cited throughout this application are hereby incorporated by reference. The appropriate components, processes, and methods of those patents, applications and other documents may be selected for the present invention and embodiments thereof.










TABLE 1

ID	STRUCTURE	<i>S. aureus</i>	<i>E. hirae</i>	<i>E. coli</i>
KA		**	**	*
KB		***	***	**
KC		**	**	*
KD		**	**	*
KE		**	***	*
KF		***	***	*
KH		**	**	**
KI		**	**	*
KJ		**	**	*
KK		**	**	**
KL		**	**	*











KM		**	**	**
KN		***	**	**
KO		**	**	**
KP		**	**	*
KQ		**	**	**
KR		**	**	**
KS		*	*	**
KT		*	*	*
KU		**	*	***
KV		**	**	**











KW		**	**	*
KX		**	**	*
KY		*	*	*
KZ		**	**	*
LA		**	**	*
LB		**	**	*
LC		**	**	*
LD		**	***	*
LE		**	**	*
LF		*	*	*












LG		**	**	*
LH		**	**	*
LI		**	**	*
LJ		**	**	*
LK		**	*	*
LM		**	**	*
LN		**	**	*
LO		**	**	*
LP		**	**	**












LQ		*	*	*
LR		**	**	**
LS		**	**	**
LT		**	**	**
LU		**	**	*
LV		*	*	*
LW		**	**	**
LX		**	**	*
LY		*	*	*












LZ		*	*	*
MA		**	**	*
MB		*	*	*
MC		*	*	*
MD		**	**	**
ME		*	**	*
MF		*	*	*
MG		**	**	*
MH		**	**	**

MI		**	**	*
MK		*	**	**
ML		**	**	**
MM		**	*	**
MN		*	*	*
MO		**	**	*
MP		**	**	**
MQ		*	*	*
MR		*	**	*
MS		***	***	**

MT		*	*	*
MU		**	**	*
MV		**	**	*
MW		**	**	*
MX		**	**	*
MY		**	**	*
MZ		**	**	**
NA		**	**	*
NB		*	*	*
NC		*	*	*












ND		*	*	*
NE		***	***	***
NF		*	*	*
NG		*	*	*
NH		*	*	*
NI		***	**	**
NJ		**	**	**
NK		**	**	*
NL		**	**	**
NM		**	**	**
NO		**	**	**








NP		**	**	**
NQ		*	*	*
NR		**	**	**
NS		**	**	**
NT		**	**	**
NU		***	***	***
NV		*	*	*
NW		*	***	*
NX		***	***	**
NY		*	***	*
NZ		**	**	*

OA		**	**	*
OB		**	**	*
OC		*	*	*
OD		***	NT	***
OE		*	*	*
OF		*	NT	**
OG		**	NT	**
OH		***	NT	***
OI		**	NT	*
OJ		**	NT	*
OK		**	NT	**

OL		*	NT	*
OM		**	NT	*
ON		**	NT	*
OO		**	NT	**
OP		**	NT	**
OQ		**	NT	*
OR		*	NT	*
OS		*	NT	*
OT		*	NT	*
OU		**	NT	*


OV		NT	NT	NT
OW		NT	NT	NT
OX		NT	NT	NT
OY		NT	NT	NT
OZ		NT	NT	NT
PA		NT	NT	NT
PB		NT	NT	NT
PC		NT	NT	NT
PD		NT	NT	NT
PE		NT	NT	NT
PF		NT	NT	NT

PG		NT	NT	NT
PH		NT	NT	NT
PI		NT	NT	NT
PJ		NT	NT	NT
PK		NT	NT	NT
PL		NT	NT	NT
PM		NT	NT	NT
PN		NT	NT	NT
PO		NT	NT	NT
PP		NT	NT	NT
PQ		NT	NT	NT

PR		NT	NT	NT
PS		NT	NT	NT
PT		NT	NT	NT
PU		NT	NT	NT
PV		NT	NT	NT
PW		NT	NT	NT
PX		NT	NT	NT

CLAIMS

1. A minocycline compound of formula I:



wherein:

X is $\text{CHC}(\text{R}^{13}\text{Y}'\text{Y})$, CR^6R^6 , S, NR^6 , or O;

10 R^2 , R^4 , $\text{R}^{4'}$, R^7 and $\text{R}^{7'}$ are each hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety;

R^4 is $\text{NR}^4\text{R}^{4'}$, alkyl, alkenyl, alkynyl, aryl, hydroxyl, halogen, or hydrogen;

$\text{R}^{2'}$, R^3 , R^{10} , R^{11} and R^{12} are each hydrogen or a pro-drug moiety;

15 R^5 is hydroxyl, hydrogen, thiol, alkanoyl, aroyl, alkaroyl, aryl, heteroaromatic, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, alkyl carbonyloxy, or aryl carbonyloxy;

R^6 and $\text{R}^{6'}$ are independently hydrogen, methylene, absent, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;

20 R^9 is nitro, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylalkyl, amino, arylalkenyl, arylalkynyl, thionitroso, or $-(\text{CH}_2)_{0-3}\text{NR}^{9c}\text{C}(=\text{Z}')\text{ZR}^{9a}$;

Z is $\text{CR}^{9d}\text{R}^{9e}$, S, NR^{9b} or O;

Z' is NR^{9f} , O or S;

25 R^{9a} , R^{9b} , R^{9c} , R^{9d} , R^{9e} and R^{9f} are each independently hydrogen, acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety;

R^8 is hydrogen, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;

30 R^{13} is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;

Y' and Y are each independently hydrogen, halogen, hydroxyl, cyano, sulfhydryl, amino, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl, and pharmaceutically acceptable salts, esters and prodrugs thereof.

2. The minocycline compound of claim 1, wherein R^4 is $NR^{4'}R^{4''}$; X is $CR^6R^{6'}$; R^2 , $R^{2'}$, R^5 , R^6 , $R^{6'}$, R^8 , R^9 , R^{10} , R^{11} , and R^{12} are each hydrogen; and, $R^{4'}$, $R^{4''}$, $R^{7'}$, and $R^{7''}$ are each lower alkyl.
- 5 3. The minocycline compound of claim 2, wherein $R^{4'}$, $R^{4''}$, $R^{7'}$, and $R^{7''}$ are each methyl.
4. The minocycline compound of any one of claims 1-3, wherein R^9 is substituted or unsubstituted aryl.
- 10 5. The minocycline compound of claim 4, wherein R^9 is substituted or unsubstituted phenyl.
6. The minocycline compound of claim 5, wherein R^9 is unsubstituted phenyl.
- 15 7. The minocycline compound of claim 5, wherein R^9 is substituted with one or more substituents selected from the group consisting of halogen, hydroxyl, alkoxy, formyl, alkylcarbonyloxy, arylcarbonyloxy, carboxyl, alkoxycarbonyloxy, aryloxy, aryloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonate, phosphinate, cyano, amino, acylamino, amido, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.
- 20 8. The minocycline compound of claim 7, wherein R^9 is substituted with one or more substituents selected from the group consisting of carboxylate, alkyl, alkenyl, alkynyl, aryl, heterocyclic, cyano, amino, halogen, alkoxy, alkoxycarbonyl, amido, alkylcarbonyl, and nitro.
- 25 9. The minocycline compound of claim 4, wherein R^9 is substituted or unsubstituted heteroaryl.
- 30 10. The minocycline compound of claim 9, wherein said heteroaryl is selected from the group consisting of furanyl, imidazolyl, benzothiophenyl, benzofuranyl, quinolinyl, isoquinolinyl, benzodioxazolyl, benzoxazolyl, benzothiazolyl, benzoimidazolyl, methylenedioxyphenyl, indolyl, thienyl, pyrimidyl, pyrazinyl, purinyl, pyrazolyl, oxazolyl, isooxazolyl, naphthridinyl, thiazolyl, isothiazolyl, or deazapurinyl.
- 35


11. The minocycline compound of claim 10, wherein said heteroaryl is thienyl or benzofuranyl.
- 5 12. The minocycline compound of anyone of claims 1-3, wherein R⁹ is substituted or unsubstituted alkynyl.
13. The minocycline compound of claim 12, wherein said substituted alkynyl group is substituted with a substituted or unsubstituted aryl group.
- 10 14. The minocycline compound of claim 13, wherein said aryl group is substituted or unsubstituted phenyl.
- 15 15. The minocycline compound of claim 14, wherein said phenyl group is substituted with a group selected from alkyl, alkenyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, alkyloxycarbonyl, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, aralkyl, phosphonato, phosphinato, cyano, 20 amino, acylamino, amido, imino, sulfhydryl, alkylthio, sulfate, arylthio, thiocarboxylate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, cyano, azido, heterocyclyl, alkylaryl, aryl and heteroaryl.
- 25 16. The minocycline compound of claim 13, wherein said aryl group is heteroaryl.
17. The minocycline compound of claim 12, wherein said alkynyl group is substituted with alkyl, alkenyl, carboxylate, silyl, aralkyl, or a alkyloxycarbonyl group.
- 30 18. The minocycline compound of claim 15, wherein said alkyl substituent is aminoalkyl.
19. The minocycline compound of claim 18, wherein said aminoalkyl is substituted with a alkylsulfonamide group.
- 35 20. The minocycline compound of claim 17, wherein said alkynyl group is substituted with a cycloalkenyl group.


21. The minocycline compound of claim 20, wherein said cycloalkenyl group is cyclopentenyl.
22. The minocycline compound of any one of claims 1-3, wherein R^9 is alkyl.
23. The minocycline compound of claim 22, wherein said alkyl group is substituted with one or more substituents selected from the group consisting of halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonate, phosphinate, cyano, amino, acylamino, amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamido, nitro, alkenyl, cyano, azido, heterocyclyl, alkylaryl, aryl and heteroaryl.
24. The minocycline compound of claim 22, wherein said alkyl group comprises a ring.
25. The minocycline compound of claim 24, wherein said alkyl group is 2-cyclopentylethyl.
26. The minocycline compound of anyone of claims 1-3, wherein R^9 is $-(CH_2)_{0-3}NR^{9c}C(=Z')ZR^{9a}$.
27. The minocycline compound of claim 26, wherein R^9 is $-NR^{9c}C(=Z')ZR^{9a}$.
28. The minocycline compound of claim 26, wherein R^9 is $-CH_2NR^{9c}C(=Z')ZR^{9a}$.
29. The minocycline compound of claim 27 or 28, wherein R^{9c} is hydrogen.
30. The minocycline compound of any one of claims 27-29, wherein Z' is S.
31. The minocycline compound of any one of claims 27-29, wherein Z' is O.
32. The minocycline compound of any one of claims 27-31, wherein Z is NR^{9b} .
33. The minocycline compound of any one of claims 27-31, wherein Z is O.

34. The minocycline compound of any one of claims 27-31, wherein Z is S.
35. The minocycline compound of claim 32, wherein R^{9b} is hydrogen.
- 5 36. The minocycline compound of anyone of claims 26-35, wherein R^{9a} is aryl.
37. The minocycline compound of claim 36, wherein R^{9a} is substituted or unsubstituted phenyl.
- 10 38. The minocycline compound of claim 36, wherein said phenyl group is substituted with one or more substituents selected from the group consisting of halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl,
- 15 aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino, acylamino, amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, acetyl, alkyl, cyano, azido, heterocyclyl, alkylaryl, aryl and heteroaryl.
- 20 39. The minocycline compound of claim 38, wherein said substituents selected from nitro, alkoxy, alkyl, acyl, halogen, or amino.
40. The minocycline compound of claim 39, wherein said amino group is dialkylamino.
- 25 41. The minocycline compound of claim 39, wherein said alkoxy group is methoxy.
42. The minocycline compound of claim 39, wherein said alkoxy group is methylenedioxy.
43. The minocycline compound of claim 41, wherein said alkoxy group is perhalogenated.
- 30 44. The minocycline compound of claim 43, wherein said alkoxy group is perfluoromethoxy.
45. The minocycline compound of claim 39, wherein said alkyl group is methyl, ethyl,
- 35 propyl, butyl, or pentyl.

46. The minocycline compound of claim 39, wherein said halogen is fluorine, chlorine, bromine, or iodine.
47. The minocycline compound of claim 36, wherein said phenyl group is unsubstituted phenyl, *para*-nitrophenyl, *para*-methoxy phenyl, *para*-perfluoromethoxy phenyl, *para*-acetyl phenyl, 3, 5-methylenedioxyphenyl, 3,5-diperfluoromethyl phenyl, *para*-bromo phenyl, *para*-chloro phenyl, or *para*-fluoro phenyl.
48. The minocycline compound of claim 38, wherein R^{9a} is arylcarbonyl.
49. The minocycline compound of claim 36, wherein R^{9a} is biaryl.
50. The minocycline compound of claim 49, wherein R^{9a} is naphthyl.
51. The minocycline compound of any one of claims 26-35, wherein R^{9a} is substituted or unsubstituted alkyl.
52. The minocycline compound of claim 51, wherein R^{9a} is unsubstituted alkyl.
53. The minocycline compound of claim 52, wherein R^{9a} is methyl, ethyl, propyl, butyl, or pentyl.
54. The minocycline compound of claim 51, wherein said alkyl is substituted with one or more substituents selected from the group consisting of halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxy carbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino, acylamino, amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, alkenyl, heterocyclyl, alkylaryl, aryl and heteroaryl.
55. The minocycline compound of any one of claims 26-35, wherein R^{9a} is substituted or unsubstituted alkenyl.
56. The minocycline compound of claim 55, wherein R^{9a} is pent-1-enyl.

57. The minocycline compound of claim 26, wherein Z' is NH, Z is NH, and R^{9a} is alkyl.
58. The minocycline compound of any one of claims 1-3, wherein R⁹ is -N=S.
59. The minocycline compound of any one of claims 1-3, wherein R⁹ is aminoalkyl.
60. The minocycline compound of claim 59, wherein said aminoalkyl is alkylaminoalkyl.
61. The minocycline compound of any one of claims 1-3, wherein R⁹ is substituted or unsubstituted alkyl amino.
62. The minocycline compound of claim 61, wherein said alkyl amino is substituted with an aryl group.
63. The minocycline compound of claim 62, wherein said aryl group is substituted or unsubstituted phenyl.
64. The minocycline compound of claim 63, wherein said substituted phenyl is methylenedioxyphenyl or *para*-perfluoromethoxyphenyl.
65. A minocycline compound or a pharmaceutically acceptable salt thereof selected from the group consisting of:





66. A method for treating a tetracycline responsive state in a mammal, comprising administering to said subject a minocycline compound of claim 1 or 65, such that said subject is treated.

67. The method of claim 66, wherein said tetracycline responsive state is a bacterial infection.

5 68. The method of claim 67, wherein said bacterial infection is associated with *E. coli*.

69. The method of claim 68, wherein said bacterial infection is associated with *S. aureus*.

70. The method of claim 68, wherein said bacterial infection is associated with *E. faecalis*.
10


71. The method of claim 67, wherein said bacterial infection is resistant to other tetracycline antibiotics.

72. The method of claim 66, wherein said minocycline compound is administered with a
15 pharmaceutically acceptable carrier.

73. The method of claim 66, wherein said subject is a human.

74. A pharmaceutical composition comprising a therapeutically effective amount of a
20 minocycline compound of claim 1 or 65 and a pharmaceutically acceptable carrier.

75. A 9-substituted minocycline compound of the formula:



(II)

wherein:

25 R^{4'}, R^{4''}, R^{7'}, and R^{7''} are each alkyl; and

R⁹ is a pyridylethynyl group; an alkenylcarbamate group; a halo group; an alkylacrylate group; a naphthyl group; a haloacetyl group; an alkyl carbamate group; a cyclopentyl or cyclopentenyl group; a benzofuranyl group; a phenylpropiononeamino group; a tosylamino group; a methoxypyridyl group; an alkeneamino group; an N-t-butyl group; a t-butylamide group; a hydroxybutylamino group; a hydroxypropylamino group; a phenyl group; 30 a nitrophenyl group; a nitrophenylalkynyl group; an aminophenyl group; an alkoxyphenyl group; a halophenyl urea group; a cyanophenyl group; a carboxyphenyl group; an acylphenyl group; an alkylphenyl group; a halophenyl group; an alkoxyphenyl group; a

carboxyalkylphenyl group; a phenylalkynyl group; an alkynyl group; an alkylglycineethylester group; a styrene group; a thiophene group; and an alkylaminophospho group; and pharmaceutically acceptable salts thereof.

- 5 76. The 9-substituted minocycline compound of claim 74, wherein said compound is 9-isopropenyl carbamate minocycline, 9-(2-pyridylethynyl) minocycline, 9-iodo minocycline, 9-butylacrylate minocycline, 9-naphthyl minocycline urea, 9-chloroacetyl minocycline, 9-neopentyl minocycline carbamate, 9-cyclopentene minocycline, benzofuranyl minocycline, 9-(phenylpropiononeamino) minocycline, 9-tosylamino minocycline, 9-(2-methoxy-3-pyridyl)
- 10 minocycline, 9-(N-2'-hydroxydecyl-9'-ene-amino) minocycline, N-t-butyl-minocycline, 9-BOC-NH minocycline, 9-(N-2'-hydroxybutylamino) minocycline, 9-(N-3-chloro,2-hydroxylpropylamino) minocycline, 9-phenyl minocycline, 9-p-tolyl minocycline, 9-3'-nitrophenyl minocycline, 9-(4-nitrophenylethynyl) minocycline, 9-(3-aminophenyl)
- 15 minocycline, 9-(4-chloro,2-trifluoromethylphenyl) minocycline urea, 9-(p-methoxyphenyl) minocycline, 9-(4'-methoxyphenyl) minocycline, 9-(3,4-methylenedioxyphenyl) minocycline, 9-(4'-cyanophenyl) minocycline, 9-(4'-carboxyphenyl) minocycline, 9-(3-formylphenyl)
- 20 minocycline, 9-(4'-t-butylphenyl) minocycline, 9-(3-chlorophenyl) minocycline, 9-(2',4'-difluorophenyl) minocycline, 9-(3,4-difluorophenyl) minocycline, 9-(4'-chlorophenyl) minocycline, 9-(3,4-dichlorophenyl) minocycline, 9-(4'-trifluoromethylphenyl) minocycline, 9-(3-ethoxyphenyl) minocycline, 9-(4-carboxymethylphenyl) minocycline, 9-(phenylethynyl)
- 25 minocycline, 9-(3-hydroxyphenylethynyl) minocycline, 9-(p-tolyethynyl) minocycline, 9-(p-methoxyphenylethynyl) minocycline, 9-ethynyl minocycline, 9-(p-fluoroethynyl) minocycline, 9-(trimethylsilylethynyl) minocycline, 9-(propionyl) minocycline, 9-(cyclohexenylethynyl) minocycline, 9-(1-cyclohexyl-1-hydroxyethynyl) minocycline, 9-propylglycineethylester
- minocycline HCl, or 9-methylglycineethylester minocycline, 9-styrene minocycline, 9-4'-fluorostyrene minocycline, 9-2-thiophene minocycline, 9-(5'-chloro-2'-thiophene) minocycline, 9-(p-methoxyphenylaminophospho) minocycline, 9-(phenylaminophospho) minocycline, 9-(p-methoxyphenylaminophospho) minocycline, or 9-(phenylaminophospho) minocycline.

- 30 77. A method for treating a tetracycline responsive state in a subject, comprising administering to said subject a 9-substituted minocycline compound of claim 75 or 76, such that said tetracycline responsive state in said subject is treated.

78. The method of claim 77, wherein said tetracycline responsive state is a bacterial
- 35 infection.

79. The method of claim 78, wherein said bacterial infection is associated with *E. coli*, *S. aureus*, or *E. faecalis*.

5 80. The method of claim 78, wherein said bacterial infection is resistant to other tetracycline antibiotics.

81. The method of claim 77, wherein said compound is administered with a pharmaceutically acceptable carrier.

10 82. A minocycline compound selected from the group listed in Table 1.

83. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim, 75, 76, or 82 and a pharmaceutically acceptable carrier.

15

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 January 2002 (17.01.2002)

PCT

(10) International Publication Number
WO 02/04406 A3

(51) International Patent Classification⁷: **C07C 237/26,**
A61K 31/65

(21) International Application Number: **PCT/US01/20721**

(22) International Filing Date: **29 June 2001 (29.06.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/216,659 7 July 2000 (07.07.2000) US
60/275,621 13 March 2001 (13.03.2001) US

(71) Applicants: **TRUSTEES OF TUFTS COLLEGE**
[US/US]: Ballou Hall, 4th Floor, Medford, MA 02155
(US). **PARATEK PHARMACEUTICALS, INC.** [US/US];
75 Kneeland Street, Boston, MA 02111 (US).

(72) Inventors: **NELSON, Mark, L.**; 735 Worcester Road,
Wellesley, MA 02481 (US). **FRECHETTE, Roger**; 40
Estate Lane, Reading, MA 01867 (US). **VISKI, Peter**;
887 West Roxbury Parkway, Brookline, MA 02467 (US).
ISMAIL, Mohamed; 5 Hunt Road, Bedford, MA 01730
(US). **BOWSER, Todd**; 88 Haggerty Road, Charlton, MA
01507 (US). **DUMORNAY, Jimmy**; 25 Kendall Street,
Walpole, MA 02081 (US). **RENNIE, Glen**; 11 Clark
Road, South Weymouth, MA 02190 (US). **LIU, Gui**;
73 Edward Street, Medford, MA 02155 (US). **KOZA,**
Darrell; 16 Ledward Avenue, Westerly, RI 02891 (US).
SHEAHAN, Paul; 103 Hayden Rowe Street, Hopkinton,
MA 01748 (US). **STAPLETON, Karen**; 36 Bradmere
Way, Weymouth, MA 02191 (US). **HAWKINS, Paul**; 205

Walden Street, Cambridge, MA 02140 (US). **BHATIA,**
Beena; 1294 Massachusetts Avenue, Arlington, MA
02476 (US). **VERMA, Atul**; 1294 Massachusetts Avenue,
Arlington, MA 02476 (US). **MCINTYRE, Laura**; 188
Franklin Street, Apartment #2, Cambridge, MA 02139
(US). **WARCHOL, Tad**; 411 Great Road, Acton, MA
01720 (US).

(74) Agents: **HANLEY, Elizabeth, A. et al.**; Lahive & Cock-
field, LLP, 28 State Street, Boston, MA 02109 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW). Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR). OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
6 June 2002

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 02/04406 A3

(54) Title: **9-SUBSTITUTED MINOCYCLINE COMPOUNDS**

(57) Abstract: The present invention pertains, at least in part, to novel 9- substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

INTERNATIONAL SEARCH REPORT

International Application No

PC1/US 01/20721

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07C237/26 A61K31/65

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 01 74761 A (TUFTS COLLEGE) 11 October 2001 (2001-10-11) claims 1,55	1-65
X	EP 0 582 810 A (AMERICAN CYANAMID CO) 16 February 1994 (1994-02-16) page 114 -page 125; claims 1,3,7; examples 3,10,19,22,32,42,43,46	1-3,7,8, 26,32-63
X	EP 0 536 515 A (AMERICAN CYANAMID CO) 14 April 1993 (1993-04-14) claim 1	1-3,7,8, 26,32-63
X	EP 0 535 346 A (AMERICAN CYANAMID CO) 7 April 1993 (1993-04-07) claims 1-8	1-3
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

2 January 2002

Date of mailing of the international search report

09/01/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax. (+31-70) 340-3016

Authorized officer

Rufet, J

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/20721

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 01 19784 A (TUFTS COLLEGE) 22 March 2001 (2001-03-22) page 17 -page 19; example 8 ---	1-6
X	EP 0 582 790 A (AMERICAN CYANAMID CO) 16 February 1994 (1994-02-16) claim 1 ---	1-3, 7, 8, 26, 32-63
X	FR 2 208 885 A (FARMACEUTICI ITALIA) 28 June 1974 (1974-06-28) claims 1, 6, 8; examples 5-7, 23 ---	1, 22
X	US 3 338 963 A (HOWARD BOOTHE JAMES ET AL) 29 August 1967 (1967-08-29) claim 1; example 38 -----	1

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-64,74,75

Present claims 1-64, 74 and 75 relate to an extremely large number of possible compounds/pharmaceutical compositions. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds/pharmaceutical compositions claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds according to claims 65, 76 and the compounds of the examples. It is stressed that expressions like heterocyclic, substituted aryl, heteroaromatic, aroyl, aryl, alkenyl, pro-drug moiety, etc., are speculative and render a complete search impossible.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC1/US 01/20721

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0174761	A	11-10-2001	WO 0174761 A1	11-10-2001
EP 0582810	A	16-02-1994	AU 4460193 A	17-02-1994
			CA 2103861 A1	14-02-1994
			CN 1090267 A ,B	03-08-1994
			CZ 9301575 A3	16-02-1994
			EP 0582810 A1	16-02-1994
			FI 933567 A	14-02-1994
			HU 64945 A2	28-03-1994
			HU 9500672 A3	28-11-1995
			IL 106677 A	15-06-1998
			IL 119750 A	24-09-1998
			IL 119751 A	24-09-1998
			JP 6228072 A	16-08-1994
			NO 932872 A	14-02-1994
			NZ 248359 A	26-03-1996
			PL 300066 A1	21-02-1994
			PL 174230 B1	31-07-1998
			PL 175487 B1	29-01-1999
			PL 174127 B1	30-06-1998
			RU 2127255 C1	10-03-1999
			SG 47520 A1	17-04-1998
			SK 85793 A3	06-04-1994
			US 5430162 A	04-07-1995
			US 5886175 A	23-03-1999
			US 5495018 A	27-02-1996
			US 5512553 A	30-04-1996
			ZA 9305892 A	10-03-1994
EP 0536515	A	14-04-1993	AU 654049 B2	20-10-1994
			AU 2618392 A	08-04-1993
			BR 1100853 A3	07-12-1999
			CA 2079692 A1	05-04-1993
			CN 1072172 A ,B	19-05-1993
			CZ 284159 B6	12-08-1998
			CZ 9703093 A3	16-09-1998
			EP 0536515 A1	14-04-1993
			FI 924454 A	05-04-1993
			HU 63145 A2	28-07-1993
			HU 9500116 A3	28-06-1995
			IL 103320 A	06-12-1998
			IL 119590 A	12-03-1999
			JP 3186863 B2	11-07-2001
			JP 5255219 A	05-10-1993
			KR 269072 B1	16-10-2000
			MX 9205532 A1	01-04-1993
			NO 301472 B1	03-11-1997
			NZ 244585 A	26-07-1995
			PL 173311 B1	27-02-1998
			PL 172282 B1	29-08-1997
			PL 175957 B1	31-03-1999
			PL 176333 B1	31-05-1999
			SG 52361 A1	28-09-1998
			SK 114999 A3	11-07-2000
			SK 298492 A3	08-03-1995
			US 5494903 A	27-02-1996
			US 5529990 A	25-06-1996
			US 5530117 A	25-06-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/20721

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0536515	A		ZA 9207607 A	13-04-1993
EP 0535346	A	07-04-1993	US 5281628 A	25-01-1994
			AT 129697 T	15-11-1995
			AU 651734 B2	28-07-1994
			AU 2618292 A	08-04-1993
			CA 2079703 A1	05-04-1993
			CN 1071415 A ,B	28-04-1993
			CZ 285015 B6	12-05-1999
			DE 69205792 D1	07-12-1995
			DE 69205792 T2	20-06-1996
			DK 535346 T3	04-12-1995
			EP 0535346 A1	07-04-1993
			ES 2081005 T3	16-02-1996
			FI 924453 A	05-04-1993
			GR 3017978 T3	29-02-1996
			HK 1000319 A1	27-02-1998
			HU 64298 A2	28-12-1993
			HU 65659 A2	28-07-1994
			HU 9500602 A3	29-01-1996
			IL 103319 A	23-07-1996
			JP 3183729 B2	09-07-2001
			JP 5239006 A	17-09-1993
			KR 261528 B1	15-07-2000
			MX 9205573 A1	01-05-1993
			NO 300129 B1	14-04-1997
			NZ 244556 A	27-06-1994
			PH 30343 A	02-04-1997
			PL 296140 A1	02-11-1993
			PL 170939 B1	28-02-1997
			SK 297292 A3	07-12-1994
			US 5326759 A	05-07-1994
			US 5401863 A	28-03-1995
			ZA 9207608 A	13-04-1993
WO 0119784	A	22-03-2001	AU 7375600 A	17-04-2001
			WO 0119784 A1	22-03-2001
EP 0582790	A	16-02-1994	US 5284963 A	08-02-1994
			AT 174903 T	15-01-1999
			AU 4460393 A	17-02-1994
			CA 2103837 A1	14-02-1994
			CN 1083047 A ,B	02-03-1994
			CZ 9301577 A3	16-03-1994
			DE 69322708 D1	04-02-1999
			DE 69322708 T2	29-04-1999
			DK 582790 T3	23-08-1999
			EP 0582790 A1	16-02-1994
			ES 2125927 T3	16-03-1999
			FI 933566 A	14-02-1994
			GR 3029764 T3	30-06-1999
			HU 64941 A2	28-03-1994
			IL 106674 A	15-07-1998
			JP 6184075 A	05-07-1994
			KR 250603 B1	01-04-2000
			LV 12273 A	20-05-1999
			LV 12273 B	20-11-1999
			MX 9304649 A1	28-02-1994

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/20721

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0582790	A		NO 932870 A	14-02-1994
			NZ 248358 A	26-04-1996
			PH 30150 A	21-01-1997
			PL 300064 A1	21-02-1994
			PL 173923 B1	29-05-1998
			RU 2111958 C1	27-05-1998
			SG 68556 A1	16-11-1999
			SK 84993 A3	08-06-1994
			ZA 9305891 A	09-03-1994
FR 2208885	A	28-06-1974	AT 328613 B	25-03-1976
			AT 799673 A	15-06-1975
			AU 6033373 A	20-03-1975
			BE 804913 A1	18-03-1974
			CA 999855 A1	16-11-1976
			DE 2346535 A1	11-04-1974
			ES 418809 A1	16-03-1976
			FR 2208885 A1	28-06-1974
			GB 1413347 A	12-11-1975
			HU 167850 B	25-12-1975
			IE 38820 B1	07-06-1978
			JP 1151371 C	14-06-1983
			JP 49069653 A	05-07-1974
			JP 57041458 B	03-09-1982
			NL 7312648 A , B	20-03-1974
			SU 574145 A3	25-09-1977
			US 3901942 A	26-08-1975
			ZA 7307317 A	25-09-1974
US 3338963	A	29-08-1967	NONE	